172 related articles for article (PubMed ID: 24294379)
1. Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma.
Shintani M; Sangawa A; Yamao N; Kamoshida S
Int J Clin Exp Pathol; 2013; 6(12):2919-27. PubMed ID: 24294379
[TBL] [Abstract][Full Text] [Related]
2. Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
Kim GY; Lim SJ; Kim YW
Mod Pathol; 2011 Oct; 24(10):1336-47. PubMed ID: 21572400
[TBL] [Abstract][Full Text] [Related]
3. Survivin in breast lesions: immunohistochemical analysis of 196 cases.
Adamkov M; Drahošová S; Chylíková J; Výbohová D
Pol J Pathol; 2017; 68(4):297-305. PubMed ID: 29517199
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor and survivin immunostaining in gastric adenocarcinoma.
Bury J; Szumiło J; Dąbrowski A; Ciechański A; Śliwińska J; Wallner G
Pol Przegl Chir; 2012 Jul; 84(7):341-7. PubMed ID: 22935455
[TBL] [Abstract][Full Text] [Related]
5. Intracellular localization of survivin determines biological behavior in colorectal cancer.
Qi G; Tuncel H; Aoki E; Tanaka S; Oka S; Kaneko I; Okamoto M; Tatsuka M; Nakai S; Shimamoto F
Oncol Rep; 2009 Sep; 22(3):557-62. PubMed ID: 19639203
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis.
Huang YJ; Qi WX; He AN; Sun YJ; Shen Z; Yao Y
Jpn J Clin Oncol; 2013 Oct; 43(10):988-95. PubMed ID: 23894202
[TBL] [Abstract][Full Text] [Related]
7. Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma.
Adamkov M; Kajo K; Vybohova D; Krajcovic J; Stuller F; Rajcani J
Neoplasma; 2012; 59(1):30-7. PubMed ID: 22103896
[TBL] [Abstract][Full Text] [Related]
8. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma.
Qian X; Xi X; Li L
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):126-32. PubMed ID: 20724919
[TBL] [Abstract][Full Text] [Related]
9. Survivin: a promising biomarker in breast carcinoma.
Adamkov M; Halasova E; Kajo K; Machalekova K; Vybohova D; Varga I; Rajcany J
Neoplasma; 2010; 57(6):572-7. PubMed ID: 20845996
[TBL] [Abstract][Full Text] [Related]
10. Cellular localisation of survivin: impact on the prognosis in colorectal cancer.
Ponnelle T; Chapusot C; Martin L; Bouvier AM; Plenchette S; Faivre J; Solary E; Piard F
J Cancer Res Clin Oncol; 2005 Aug; 131(8):504-10. PubMed ID: 15902487
[TBL] [Abstract][Full Text] [Related]
11. Nuclear overexpression of the overexpressed in lung cancer 1 predicts worse prognosis in gastric adenocarcinoma.
Wang J; Shen H; Fu G; Zhao D; Wang W
Oncotarget; 2017 Feb; 8(6):9442-9450. PubMed ID: 28038462
[TBL] [Abstract][Full Text] [Related]
12. Loss of Hes1 expression is associated with poor prognosis in colorectal adenocarcinoma.
Ahadi M; Andrici J; Sioson L; Sheen A; Clarkson A; Gill AJ
Hum Pathol; 2016 Nov; 57():91-97. PubMed ID: 27476040
[TBL] [Abstract][Full Text] [Related]
13. Survivin expression in colorectal carcinomas: correlations with clinicopathological parameters and survival.
Kalliakmanis JG; Kouvidou Ch; Latoufis C; Kouvatseas G; Anagnostakis D; Papatheodoridis G; Koskinas J; Archimandritis A
Dig Dis Sci; 2010 Oct; 55(10):2958-64. PubMed ID: 20033843
[TBL] [Abstract][Full Text] [Related]
14. [Expression of survivin in human gastric adenocarcinomas: correlation with proliferation and apoptosis].
Yao XQ; Liu FK; Qi XP; Wu B; Yin HL; Ma HH; Shi QL; Zhou XJ; Li JS
Zhonghua Wai Ke Za Zhi; 2004 Feb; 42(3):145-8. PubMed ID: 15062058
[TBL] [Abstract][Full Text] [Related]
15. Nuclear survivin expression correlates with endoglin-assessed microvascularisation in laryngeal carcinoma.
Marioni G; Ottaviano G; Marchese-Ragona R; Fasanaro E; Tealdo G; Zanotti C; Randon B; Giacomelli L; Stellini E; Blandamura S
J Clin Pathol; 2017 Dec; 70(12):1033-1037. PubMed ID: 28446541
[TBL] [Abstract][Full Text] [Related]
16. Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer.
Deng H; Wu RL; Zhou HY; Huang X; Chen Y; Liu LJ
World J Gastroenterol; 2006 Feb; 12(7):1013-7. PubMed ID: 16534839
[TBL] [Abstract][Full Text] [Related]
17. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
[TBL] [Abstract][Full Text] [Related]
18. Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study.
Villari D; Caruso R; Grosso M; Vitarelli E; Righi M; Barresi G
Pathology; 2002 Oct; 34(5):423-6. PubMed ID: 12408340
[TBL] [Abstract][Full Text] [Related]
19. Significance of estrogen receptors and cathepsin D tissue detection in gastric adenocarcinoma.
Theodoropoulos GE; Lazaris AC; Panoussopoulos D; Davaris P; Golematis BC
J Surg Oncol; 1995 Mar; 58(3):176-83. PubMed ID: 7898114
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma.
Selemetjev S; Dencic TI; Marecko I; Jankovic J; Paunovic I; Savin S; Cvejic D
Pathol Res Pract; 2014 Jan; 210(1):30-4. PubMed ID: 24199968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
